Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $42.2222.

Several brokerages have commented on TEVA. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the sale, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.54% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after acquiring an additional 4,732 shares during the period. Focus Partners Wealth lifted its holdings in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares during the period. Franklin Resources Inc. purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $255,000. Flow Traders U.S. LLC purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $238,000. Finally, Cerity Partners LLC grew its stake in shares of Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after purchasing an additional 1,291 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $36.78 on Tuesday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. Teva Pharmaceutical Industries has a fifty-two week low of $17.33 and a fifty-two week high of $37.39. The stock has a market cap of $42.87 billion, a PE ratio of 61.31, a price-to-earnings-growth ratio of 3.93 and a beta of 0.86. The stock has a fifty day moving average of $33.52 and a 200-day moving average of $32.99.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 1.96 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.